TNK2

Across TCGA pan-cancer cohorts, TNK2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TNK2 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TNK2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TNK2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where TNK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.252	0.619	.002	59	view →
LUAD	DFS	Quartile	All	0.860	0.480	.001	15	view →
CCRCC	OS	Median	II,III,IV	0.759	0.985	.028	15	view →
LSCC	DFS	Quartile	II,III,IV	0.571	0.894	.021	4	view →
HNSC	DFS	Quartile	III,IV	0.451	0.736	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TNK2–PDAC (OS)

Open the PDAC breakdown →